HCA vs THC: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

HCA is the larger of the two ($98.80B market cap): the incumbent the market prices for continued execution (15.12x forward earnings, beta 1.10). THC is the smaller challenger ($20.94B), cheaper on forward earnings (12.92x): more room to run, but more to prove. If you believe HCA earns its premium (15.12x forward earnings, so the market expects more from it), HCA fits. If you believe in paying less for profit, THC fits at 12.92x.

HCA vs THC: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricHCATHCWhat it tells you
Market cap$98.80B$20.94BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E15.1212.92Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E15.697.67Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta1.101.20Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range59% of range73% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Reading it: THC is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how HCA and THC affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HCA and THC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HCA and THC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does HCA Healthcare (HCA) do?

HCA Healthcare is the largest for-profit hospital system in the United States, operating a network of acute-care hospitals alongside surgery centers, urgent-care clinics, freestanding emergency rooms, and physician clinics. Its strategy centers on building dense local networks in growing Sun Belt and suburban markets, where controlling a large share of care lets it negotiate better rates with commercial insurers, recruit physicians, and spread fixed costs. In the first quarter of 2026 HCA reported revenue of about $19.1 billion, up roughly 4% year over year, with net income near $1.6 billion and diluted EPS of about $7.15, and it reaffirmed full-year 2026 guidance of roughly $76.5 billion to $80.0 billion in revenue and $15.55 billion to $16.45 billion in adjusted EBITDA. The second quarter, ended June 30, was stronger: revenue of about $20.2 billion, up roughly 9%, net income near $1.7 billion and EPS of $7.59 against a $7.50 estimate. The third quarter, ended September 30, brought revenue of about $19.9 billion, up roughly 3.6% and above the roughly $19.3 billion expected, net income near $1.6 billion and EPS of $7.22, well ahead of the $6.63 estimate and the fifth straight beat. Trailing twelve-month revenue now stands near $78.7 billion, with net income of about $6.8 billion.

Full HCA guide

What does Tenet Healthcare (THC) do?

Tenet Healthcare is a diversified for-profit healthcare services company that operates through three segments. Hospital Operations runs acute care and specialty hospitals plus affiliated outpatient facilities, imaging centers, and physician practices. United Surgical Partners International (USPI) is the ambulatory segment and operates or holds interests in hundreds of ambulatory surgery centers and surgical hospitals across dozens of states, making it the largest ASC platform in the country. Conifer Health Solutions provides revenue cycle management and value-based care services to hospitals and health systems.

Full THC guide

HCA vs THC: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • HCA drivers: Scale and local-market density; Outpatient and ambulatory expansion.
  • THC drivers: USPI ambulatory surgery leadership; Business mix shift toward higher-margin services.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is reimbursement and health-care policy. For THC, hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix.

HCA or THC: which should you pick?

If the story you believe is HCA's (Scale and local-market density), HCA is the more direct way to own it; if it is THC's (USPI ambulatory surgery leadership), THC is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HCA and THC guides.

HCA vs THC: the full fundamentals

HCA. At about $473 on November 20, 2026, HCA trades near 15.7x trailing and 15.1x forward earnings and under 10x EV/EBITDA, the multiple of a steady, cash-generative operator more than a high-growth stock, so it reflects reimbursement stability and buyback-driven per-share growth more than rapid revenue expansion. Analysts expect 2026 EPS of about $30.09 rising to about $31.29 in 2027, roughly 4% growth. The biggest variable is still policy: the 2026 guidance bakes in an ACA-subsidy and Medicaid hit that management is partly offsetting, and the 2027 outlook that usually arrives with the January report will show how much of it carries over.

THC. Tenet still trades at a modest earnings multiple typical of hospital operators (a discount that prices in reimbursement and leverage risk), even after a 32% rise in 2026 as USPI mix shift, margin gains, and deleveraging improved earnings quality. The forward P/E near 12.9x sits well above the trailing 7.7x because analysts expect 2027 EPS of about $20.36, down from about $22.53 in 2026, after a run of large beats. Fourth-quarter consensus is about $5.24 of EPS on $5.67 billion of revenue, and the average of 22 analyst targets is about $309.

Headline figures (approximate, November 2026): HCA shows revenue (ttm) ~$78.7 billion; Q3 2026 ~$19.9 billion, up ~3.6% year over year, net income (ttm) ~$6.8 billion, ~8.6% net margin, q3 2026 eps vs estimate $7.22 vs $6.63, full-year 2026 guidance (given with q1) Revenue ~$76.5 billion to $80.0 billion; adjusted EBITDA ~$15.55 billion to $16.45 billion; THC shows revenue (ttm) ~$22.2 billion (Q3 2026 +~6.5% yoy), q3 2026 adjusted eps ~$6.64 vs ~$4.68 est., net income (ttm) ~$2.9 billion (net margin ~13%), operating margin (ttm) ~19%.

The bottom line: HCA vs THC

HCA and THC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined HCA and THC exposure against your real portfolio. It is not an investment adviser.

Wondering how HCA or THC fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about HCA Healthcare

Ask Walnut's AI anything about HCA and see how it fits what you own.

FAQ

What is the difference between HCA and THC?

+

HCA Healthcare is the largest for-profit hospital system in the United States, operating a network of acute-care hospitals alongside surgery centers, urgent-care clinics, freestanding emergency rooms, and physician clinics. Tenet Healthcare is a diversified for-profit healthcare services company that operates through three segments. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is HCA or THC the better stock?

+

Neither is universally better. HCA is the larger incumbent; THC is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, HCA or THC?

+

On forward P/E (as of November 2026), HCA trades at 15.12x and THC at 12.92x, so THC is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both HCA and THC?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of HCA vs THC?

+

HCA: The dominant risk is reimbursement and health-care policy. HCA depends on a mix of commercial, Medicare, and Medicaid payers, and the expiration of enhanced ACA marketplace subsidies plus Medicaid payment changes could pressure adjusted EBITDA by several hundred million dollars, with more uninsured and self-pay patients raising bad-debt and charity-care costs. Labor is a structural cost pressure: nursing and physician wages, contract-labor use, and staffing shortages can compress margins quickly. Supply, drug, and equipment costs, including exposure to tariffs and supply-chain disruption, add further cost volatility. HCA also carries substantial debt from years of buybacks, about $52.4 billion against roughly $1.0 billion of cash as of September 2026, so higher interest rates raise financing costs. Revenue growth slowed to about 3.6% in the third quarter from about 9% in the second, and analysts model only about 3% revenue growth in 2027, so per-share gains lean increasingly on buybacks and cost control. Litigation, regulatory scrutiny of billing and pricing practices, and local competition from nonprofit systems and physician-owned outpatient centers round out the risk set. THC: Hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix. Labor costs, physician and nurse staffing, and wage inflation weigh on the hospital segment. The company still carries meaningful debt despite deleveraging, about $13.2 billion at the end of September 2026, so higher-for-longer interest rates matter. Bad debt from uninsured and underinsured patients, regulatory and billing scrutiny, and cyclicality in elective surgical volumes are additional risks; peer Community Health Systems said in November 2026 that it sees patients delaying surgeries into next year as costs squeeze them. Acquisition-led USPI growth depends on continued access to attractive surgery-center deals at reasonable prices. After a roughly 32% gain in 2026, expectations are higher too: consensus calls for 2027 EPS of about $20.36, about 10% below the roughly $22.53 expected for 2026, so the market is not pricing in another year of earnings growth, and a stumble against that bar could weigh on the shares. The trailing P/E near 8x also flatters the stock, because the trailing $2.9 billion of net income runs well ahead of what analysts expect to recur.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell HCA or THC; figures are approximate and dated (as of November 2026). Verify current data before investing.